Evofem Biosciences

Evofem Biosciences announces cost reduction measures

SAN DIEGOMarch 21, 2023 /PRNewswire/ — Evofem Biosciences, Inc., (OTCQB: EVFM) (the “Company”) today announced it has implemented measures to lower its operating expenses, with the goal of reaching cash flow break even by year-end 2023. These measures include a 39% reduction of payroll expenses through a combination of:

–  Salary cuts for certain employees, including a 40% reduction in Chief Executive Officer compensation and a 20% reduction in pay for other continuing members of the executive team vs. prior year levels; 

–  Consolidation of three sales territories;

–  Elimination of eight office and management positions, including the Chief Commercial Officer role, effective March 17, 2023.

“It was a difficult decision to restructure our already very small workforce and ask remaining team members to work harder for less pay. The team members who stay with the organization are united behind our common goals and worthy mission, and have the heart, head, and backbone to change women’s health forever.  This decision is critical to our long-term success and our ability to align resources to enable us to continue providing Phexxi to women seeking hormone-free prescription contraception,” said Saundra Pelletier, Evofem’s Chief Executive Officer.

The Company expects this reduction in force to be substantially completed in the first quarter of 2023.

About Evofem Biosciences, Inc. 

Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Source: PR Newswire